CEBPZ and neoplasm: The clinical differences attributed to these gender factors may be linked to variations in pathophysiological mechanisms between the sexes, such as tumor incidence (Tan et al., 2023), expression of NMDAR (Hsu et al., 1999), reductions in CBF (Miao and Wang, 2024), and BCSFB vulnerability (Candeloro et al., 2024), as previously mentioned.